Gland PharmaNSE:GLAND +0.66%86 Net Current Asset Value is ₹326.17 as of Mar. 2026, which is 100% below its 10-year median of 6.89. GuruFocus rates NSE:GLAND with a GF Score™ of 86/100 and a GF Value™ of ₹2,133.59 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 609 Drug Manufacturers companies, Gland Pharma ranks worse than 61.25% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Gland Pharma's net current asset value per share for the quarter that ended in Mar. 2026 was ₹326.17.
The historical rank and industry rank for Gland Pharma's Net Current Asset Value or its related term are showing as below:
NSE:GLAND'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.43 Med: 6.89 Max: 10.39
Current: 7.55
During the past 9 years, the highest Price-to-Net-Current-Asset-Value Ratio of Gland Pharma was 10.39. The lowest was 3.43. And the median was 6.89.
NSE:GLAND's Price-to-Net-Current-Asset-Value is ranked worse than 61.25% of 609
companies
in the Drug Manufacturers industry
Industry Median: 5.72
vs NSE:GLAND: 7.55
Gland Pharma (NSE:GLAND) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Gland Pharma Net Current Asset Value Related Terms
Gland Pharma Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Gland Pharma's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:GLAND vs ZTS, UTHR: Net Current Asset Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Gland Pharma's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gland Pharma Price-to-Net-Current-Asset-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gland Pharma's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Gland Pharma's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of ₹326.17 mean?
Gland Pharma (NSE:GLAND) has a Net Current Asset Value of ₹326.17 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Gland Pharma and its competitors. This is 4634% above median its historical median of 6.89. Over the past decade, Gland Pharma's Net Current Asset Value has ranged from 3.43 to 10.39. According to the industry distribution chart, Gland Pharma ranks #373 out of 609 companies in the Drug Manufacturers industry, placing it in the top 61.2%.
Is Gland Pharma's Net Current Asset Value too high?
Gland Pharma's current Net Current Asset Value of ₹326.17 is 4634% above median its 10-year median of 6.89. Over the past 10 years, this metric has ranged from a low of 3.43 to a high of 10.39. Based on the distribution chart, Gland Pharma ranks #373 out of 609 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Gland Pharma has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gland Pharma's Net Current Asset Value compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Gland Pharma ranks #373 out of 609 companies for Net Current Asset Value. This places Gland Pharma in the lower half of its industry. The industry median Net Current Asset Value is 5.72. Historically, Gland Pharma's own Net Current Asset Value has ranged from 3.43 to 10.39 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Drug Manufacturers company?
The median Net Current Asset Value among Drug Manufacturers companies is 5.72, based on 609 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Gland Pharma and its competitors. For the Drug Manufacturers industry, the median Net Current Asset Value is 5.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gland Pharma's current Net Current Asset Value is ₹326.17, which is 4634% above median its own 10-year median of 6.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gland Pharma stock overvalued right now?
Based on GuruFocus' analysis, Gland Pharma (NSE:GLAND) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,133.59, compared to a current price of ₹2,462.30 — trading 15.4% above its estimated fair value. The current Net Current Asset Value is ₹326.17, which is 4634% above median its 10-year median of 6.89. Gland Pharma's overall GF Score™ is 86/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Gland Pharma (NSE:GLAND), the current Net Current Asset Value is ₹326.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gland Pharma (NSE:GLAND) Overvalued in 2026?
Based on GuruFocus' analysis, Gland Pharma stock appears to be overvalued.
The current stock price of ₹2,462.30 is trading 15.4% above its estimated GF Value™ of ₹2,133.59.
GuruFocus considers Gland Pharma to be Modestly Overvalued.
Key valuation signals for NSE:GLAND:
Net Current Asset Value: ₹326.17 (4634% above median its 10-year median of 6.89)
GF Value™: ₹2,133.59 vs. price of ₹2,462.30 (15.4% above fair value)
No single metric tells the full story. See the NSE:GLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, and Daptomycin Injection, among others. The group is also involved in a vast range of therapeutic categories, including Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarials, Cardiology, and more, to Hormones and related Drugs, Fertility Supplements, and GnRH Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA, and the rest from Europe, India, Canada, Australia, and other regions.
86GF Score
Get the complete analysis for NSE:GLAND
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GLAND has been successfully added to your 
